Eli Lilly has agreed to buy a gene-editing programme for cardiovascular diseases from Beam Therapeutics in a deal, valued at up to $600 million, that ties in with the biot
Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot t
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.